ArticleInfection2014
Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections.
Article in Infection, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Guideline
- Risk factors for hospitalized patients with resistant or multidrug-resistantAntimicrobial resistance and infection control · 2018Pooled it
- Estimating the burden of antimicrobial resistance: a systematic literature review.Antimicrobial resistance and infection control · 2018Pooled it
- Sphingosine synergizes with polymyxin antibiotics againstMicrobiology (Reading, England) · 2026Article
- Exploring the antibacterial potential of arthrocolins against extensively drug-resistantFrontiers in microbiology · 2025Article
- Extensively drug-resistantFrontiers in microbiology · 2024Article
- An Overview of Selected Bacterial Infections in Cancer, Their Virulence Factors, and Some Aspects of Infection Management.Biology · 2023Review
- Special Issue: "Antimicrobial Resistance inMicroorganisms · 2023Article
- Better Outcome of Off-Label High-Dose Ceftazidime in Hemato-Oncological Patients with Infections Caused by Extensively Drug-ResistantMediterranean journal of hematology and infectious diseases · 2023Article
- Risk Factors and Outcomes for Multidrug ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Evolution of Habitat-Dependent Antibiotic Resistance in Pseudomonas aeruginosa.Microbiology spectrum · 2022Article
- The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-ResistantAntibiotics (Basel, Switzerland) · 2022Review
- XDR-Antibiotics (Basel, Switzerland) · 2022Article
- A rapid evidence assessment exploring whether antimicrobial resistance complicates non-infectious health conditions and healthcare services, 2010-20.JAC-antimicrobial resistance · 2021Review
- Antimicrobial Susceptibility Trends and Risk Factors for Antimicrobial Resistance inJournal of Korean medical science · 2021Article
- Article
- Coming from the Wild: Multidrug Resistant Opportunistic Pathogens Presenting a Primary, Not Human-Linked, Environmental Habitat.International journal of molecular sciences · 2021Review
- Article
- Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.Antimicrobial agents and chemotherapy · 2020Article
- Risk Factors for Mortality among Patients withJournal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the characteristics and outcomes of cancer patients with extensively drug-resistant (XDR) Pseudomonas aeruginosa infections.
methodsThis was a retrospective cohort of P. aeruginosa infections in cancer patients in Crete, Greece. Patients were followed until discharge. Mortality, predictors of mortality and risk factors for XDR P. aeruginosa infection were studied.
resultsNinety seven episodes (89 patients) of P. aeruginosa infections (52 with bacteremia) were included in the study. In 22 cases, the infection was due to XDR isolates. All XDR isolates were susceptible to colistin and variably resistant to almost all other antibiotics. The multivariate analysis showed that the independent risk factors for XDR P. aeruginosa infection were hematologic malignancy (OR 40.7, 95 % CI 4.5-367.6) and prior fluoroquinolone use (OR 11.0, 95 % CI 2.0-60.5); lymphopenia was inversely associated with XDR infections (OR 0.16, 95 % CI 0.03-0.92). Mortality was 43 %; infection-related mortality was 24 %. Bacteremia (OR 8.47, 95 % CI 2.38-30.15), infection due to XDR isolates (OR 5.11, 95 % CI 1.15-22.62) and age (OR 1.05, 95 % CI 1.00-1.09) were independently associated with mortality.
conclusionMortality in cancer patients with P. aeruginosa infections was high. Infection due to XDR isolates was independently associated with mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.